 BOSTON--BUSINESS WIRE--- KRTX--Karuna Therapeutics, Inc. NASDAQ: KRTX, a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT xanomeline-trospium in healthy elderly volunteers. The Company had previously announced a preliminary analysis of data from the first two cohorts in the trial earlier 